1
Clinical Trials associated with gp100-fowlpox vaccine(NCI)Treatment of Patients With Metastatic Melanoma by Lymphodepleting Conditioning Followed by Infusion of TCR-Gene Engineered Lymphocytes and Subsequent Fowlpox gp100 Vaccination
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining gene-modified white blood cell infusions with interleukin-2 and vaccine therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying how well giving gene-modified white blood cells when given together with interleukin-2 and vaccine therapy works in treating patients with metastatic melanoma.
100 Clinical Results associated with gp100-fowlpox vaccine(NCI)
100 Translational Medicine associated with gp100-fowlpox vaccine(NCI)
100 Patents (Medical) associated with gp100-fowlpox vaccine(NCI)
100 Deals associated with gp100-fowlpox vaccine(NCI)